EUCTR2016-003473-17-GR进行中（未招募）1 期
A Phase 2, 24-Week Randomized, Double-blind, Placebo-Controlled Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiopathic Pulmonary Fibrosis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject is male or female = 40 years of age at the time of signing the
- •informed consent form (ICF)
- •2. Subject must understand and voluntarily sign an ICF prior to any
- •study-related assessments/procedures being conducted
- •3. Subject is willing and able to adhere to the study visit schedule and
- •other protocol requirements
- •4. Investigator has considered all available IPF treatment options with
- •the potential subject before consenting the subject for participation in
- •5. Subject was diagnosed with IPF within 5 years of Screening.
- •XML File Identifier: vOjOYhnmMOCfBq226QUqMruO/bU=
- •6. Diagnosis of IPF is supported by HRCT, as described in Table 3 and
- •Appendix G of the Protocol.
- •7. Extent of fibrotic changes (eg, honeycombing, reticular changes)
- •greater than the extent of emphysema on HRCT scan, as determined by
- •centralized review
- •8. No features supporting an alternative diagnosis on transbronchial
- •biopsy, bronchoalveolar lavage (BAL), or SLB, if performed prior to
- •9. Percent predicted forced vital capacity (% FVC) = 45% and = 95% at
- •Screening confirmed by centralized review
- •10. Change in FVC (measured in milliliters [mL]) between Screening and
- •Day 1 less than a 10% relative difference, calculated as: the absolute
- •value of 100% * (Screening FVC [mL] - Day 1 FVC [mL]) / Screening FVC
- •11. Hemoglobin-corrected percent predicted diffusion capacity of the
- •lung for carbon monoxide (DLCO) = 25% and = 90% predicted at
- •12. Able to walk = 150 meters during the 6-minute walk test (6MWT) at
- •13. Females of childbearing potential (FCBP) must:
- •a. Have two negative pregnancy tests as verified by the Investigator
- •prior to starting IP. She must agree to ongoing pregnancy testing during
- •the course of the study, and after end of study treatment. This applies
- •even if the subject practices true abstinence* from heterosexual contact.
- •b. Either commit to true abstinence* from heterosexual contact (which
- •must be reviewed on a monthly basis and source documented) or agree
- •to use two effective birth control methods (for example: birth control
- •pills, condoms, etc) at the same time, and be able to comply with,
- •effective contraception without interruption, 28 days prior to starting IP,
- •during the study therapy (including dose interruptions), and for 28 days
- •after discontinuation of IP
- •14. Male subjects must:
- •Practice true abstinence? (which must be reviewed on a monthly basis)
- •or agree to use condoms not made out of natural [animal] membrane
- •during sexual contact with a pregnant female or a female of childbearing
- •potential while participating in the study, during dose interruptions and
- •for at least 28 days following IP discontinuation, even if he has
- •undergone a successful vasectomy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 95
排除标准
- •1. Subject has any significant medical condition, laboratory abnormality,
- •or psychiatric illness that would prevent the subject from participating in
- •2. Subject has any condition including the presence of laboratory
- •abnormalities, which places the subject at unacceptable risk if he/she
- •were to participate in the study
- •3. Subject has any condition that confounds the ability to interpret data
- •from the study
- •4. Significant clinical worsening of IPF between Screening and Baseline
- •(Visit 2), in the opinion of the Investigator
- •5. Subjects with any of the following laboratory criteria:
- •White blood cell count (WBC) < 3500/mm3 (< 3.5 X 109/L) or >
- •14,000/mm3 (> 14 X 109/L)
- •Platelet count < 120,000/µL (< 120 X 109/L)
- •Serum creatinine > 1.5 mg/dL (> 132.6 µmol/L)
- •Aspartate aminotransferase (AST/SGOT) > 1.5 X upper limit of normal
- •Alanine aminotransferase (ALT/SGPT) > 1.5 X upper limit of normal
- •XML File Identifier: vOjOYhnmMOCfBq226QUqMruO/bU=
- •Total bilirubin > 2 mg/dL (> 34.2 µmol/L)
- •Hemoglobin < 10 g/dL (< 100 g/L)
- •6. Subject with a QTcF > 450 msec
- •7. Any condition other than IPF that in the opinion of the Investigator is
- •likely to result in the death of the subject within the next year
- •8. Inability to obtain reproducible, high-quality pulmonary function tests.
- •9. Evidence of clinically relevant airways obstruction (ie, FEV1/FVC <
- •0.7) at Screening and/or significant respiratory disorder/pathology (eg,
- •pulmonary arterial hypertension requiring treatment, asthma,
- •tuberculosis, sarcoidosis, hypersensitivity pneumonitis, aspergillosis,
- •asbestosis, neoplastic disease, cystic fibrosis or other interstitial lung
- •disease) other than IPF
- •10. Subject is likely to have lung transplantation during the first 24
- •weeks of the study (being on transplantation list is acceptable for
- •participation)
- •11. Impairment (other than dyspnea) limiting the ability to comply with
- •study requirements (eg, pulmonary function tests, 6-minute walk test)
- •12. Subjects using any therapy targeted to treat IPF including, but not
- •limited to, pirfenidone, nintedanib, endothelium receptor antagonists
- •(eg, bosentan, ambrisentan), interferon gamma-1b, imatinib mesylate,
- •N-acetylcysteine, azathioprine, cyclophosphamide, methotrexate,
- •mycophenolate mofetil, and cyclosporine, oral steroids (eg, prednisone >
- •12.5 mg/day or equivalent) and oral anticoagulants within 4 weeks of
- •the Screening Visit. (Note: Oral anticoagulants for conditions other than
- •IPF are permitted. Subjects should not discontinue any of these
- •therapies for the sole purpose of participating in this study.)
- •13. Use of any cytokine modulator/biologic, such as etanercept,
- •adalimumab, efalizumab, infliximab, or rituximab within 12 weeks of
- •randomization
- •14. Use of an inhaled long-acting bronchodilator within 24 hours of the
- •Screening Visit or short-acting bronchodilator within 8 hours of the
- •Screening Visit
- •15. Use of drugs that are known to cause hepatotoxicity, such as, but not
- 另有 8 项未显示
研究者
相似试验
进行中（未招募）
1 期
Investigation to Efficacy and Safety of CC-90001 in patients with Idiopathic Pulmonary FibrosisMedDRA version: 20.0Level: LLTClassification code 10067761Term: Exacerbation of idiopathic pulmonary fibrosisSystem Organ Class: 100000004855IDIOPATHIC PULMONARY FIBROSISEUCTR2016-003473-17-GBCelgene Corporation135
进行中（未招募）
1 期
A 24-week phase 2, double-blind, placebo-controlled, single-centre safety and efficacy study to evaluate overall safety and tolerability of co-administration of tesofensine and metoprolol in subjects with obesity caused by an injury in hypothalamus (HIO), and with a 24-week open-label extension, in total 48 weeksEUCTR2018-003672-12-DKSaniona A/S25
已完成
2 期
Study of Safety and Efficacy Of PF-04971729 In Patients With Type 2 Diabetes And HypertensioCTRI/2010/091/001073Pfizer Limited175
进行中（未招募）
1 期
A 12-Week, Phase 2, Randomized, Double-Blind,Placebo-Controlled Study of LY2599506 in Patientswith Type 2 Diabetes Mellitus Treated with Diet andExercise, with or without MetforminEstudio de fase 2, aleatorizado, doble ciego, de 12 semanas de duración, controlado con placebo, de LY2599506 en pacientes con diabetes mellitus tipo 2 tratados con dieta y ejercicio, con o sin metforminadiabetes mellitus tipo 2MedDRA version: 9Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2009-014958-16-ESilly S.A.120
已完成
2 期
Clinical trial to evaluate safety, tolerability, pharmacokinetic and effect on glycemic control of p1736-05 in subjects with type 2 diabetes mellitusCTRI/2010/091/006110Piramal Enterprises ltd130